Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Work In Process: 2013-2018

Historic Work In Process for Theravance Biopharma (TBPH) over the last 4 years, with Sep 2018 value amounting to $3.6 million.

  • Theravance Biopharma's Work In Process rose 379.89% to $3.6 million in Q3 2018 from the same period last year, while for Sep 2018 it was $3.6 million, marking a year-over-year increase of 379.89%. This contributed to the annual value of $66,000 for FY2017, which is 97.49% down from last year.
  • Theravance Biopharma's Work In Process amounted to $3.6 million in Q3 2018, which was up 8.33% from $3.3 million recorded in Q2 2018.
  • In the past 5 years, Theravance Biopharma's Work In Process ranged from a high of $3.6 million in Q3 2018 and a low of $66,000 during Q4 2017.
  • Over the past 3 years, Theravance Biopharma's median Work In Process value was $2.0 million (recorded in 2018), while the average stood at $2.1 million.
  • Its Work In Process has fluctuated over the past 5 years, first tumbled by 97.49% in 2017, then skyrocketed by 379.89% in 2018.
  • Theravance Biopharma's Work In Process (Quarterly) stood at $145,000 in 2014, then reached $2.6 million in 2016, then tumbled by 97.49% to $66,000 in 2017, then surged by 379.89% to $3.6 million in 2018.
  • Its Work In Process stands at $3.6 million for Q3 2018, versus $3.3 million for Q2 2018 and $2.0 million for Q1 2018.